glp 1 drugs alternative equivalency chart Promising New Science on Weight Loss Drug Alternatives A new FDA-approved obesity pill
Description
Eur J Pharmacol 2019;864:172715.ArticlePubMed 108
No affiliation, endorsement, or sponsorship by or with Novo Nordisk or Eli Lilly is implied
Surgery is invasive, Low Wang said
Once stable, monitoring every three to six months is appropriate, reducing to six-monthly when control is well established
